COUR Pharma
Funding reported, Series B, last update 2 months ago
Pharma biotech
Everything we hold on COUR Pharma, newest first. Every line links to the filing or report it came from.
This profile is thin because we hold one source document on COUR Pharma so far, not because nothing else has happened there. We only publish what we have read on a primary source and can link to. So a profile fills up as filings and reports come in, and we never seed it from an estimate. We keep profiles at this stage out of our sitemap and mark them noindex until they carry enough to be worth a search result of their own.
- 2026-06-18Headcount Not Stated Growing and expanding
COUR Pharma Announces Closing of $50 Million Series B
COUR Pharma closed a $50 million Series B for its pharma and biotech work, a stage where funds typically build out clinical and research teams, but the announcement names no hiring plans or roles.
The read-through on each line is our interpretation. The headline and figures come from the linked source. Data licensed CC BY 4.0. Back to the tracker